The Long-Term Effect of Specific Type II 5alpha-Reductase Inhibition with Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo Controlled Trial

    May 2002 in “ PubMed ”
    Alvin M. Matsumoto, Lisa Tenover, Michael R. McClung, David L. Mobley, Jack Geller, Michael J. Sullivan, John T. Grayhack, Hunter Wessells, Dov Kadmon, Malachi J. Flanagan, Gang Zhang, Joseph Schmidt, Alice Taylor, Michael D. Lee, Joanne Waldstreicher
    New to Finasteride? There is a guide in the encyclopedia. Read the guide →
    Studysummary In this study, long-term use of finasteride did not negatively impact bone mineral density in men with benign prostatic hyperplasia over a 4-year period. Our plain-language summary of this paper — not a Tressless recommendation.
    The study concluded that long-term inhibition of type II 5alpha-reductase with finasteride did not adversely affect bone mineral density in men. This conclusion was based on a 4-year, double-blind, placebo-controlled trial involving 157 men aged 46 to 76, with 117 participants having baseline and follow-up bone mineral density measurements. The results showed no significant difference in bone mineral density between the finasteride and placebo groups after 4 years, indicating that finasteride did not negatively impact bone health in the study population.
    Discuss this study in the Community →

    Research cited in this study

    5 / 5 results